PMID- 25572687
OWN - NLM
STAT- MEDLINE
DCOM- 20160512
LR  - 20150811
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 22
IP  - 9
DP  - 2015 Sep
TI  - Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: 
      final results of the phase II Ca.Pa.Be study.
PG  - 2881-7
LID - 10.1245/s10434-015-4371-0 [doi]
AB  - PURPOSE: The phase II Ca.Pa.Be trial evaluated preoperative 
      carboplatin-paclitaxel in combination with bevacizumab in triple-negative breast 
      cancer patients with previously untreated stage II-III disease. The primary aim 
      was the assessment of the rate of pathologic complete response (pCR). Secondary 
      aims included safety, breast-conserving surgery rate, and early response 
      assessment with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). 
      METHODS: Patients with hormone receptor-negative, HER-2-negative stage II-III 
      breast cancer were eligible. Treatment included paclitaxel 80 mg/mq + carboplatin 
      area under the curve (AUC) 2 on days 1, 8, and 15, combined with bevacizumab 10 
      mg/kg on days 1 and 15 each 28 days, for 5 courses. At baseline, patients 
      underwent breast DCE-MRI, followed by a single dose of bevacizumab 5 mg/kg (day 
      -6). DCE-MRI was repeated before the initiation of chemotherapy. RESULTS: 
      Forty-four patients were enrolled. Forty-three patients underwent surgery, and 22 
      (50 %) received breast-conserving surgery (conversion rate from mastectomy 
      indication at baseline, 34.4 %). A pCR in breast and axillary lymph nodes 
      occurred in 22 patients (50 %). Bevacizumab-associated adverse events (AEs) were 
      mild: G1-2 hypertension and bleeding occurred in 6 (13.6 %) and 12 (27 %) 
      patients, respectively. No G4 nonhematologic AEs were recorded. More frequent G3 
      AEs were liver function test abnormalities (6.8 %), and diarrhea and fatigue (4.5 
      % each). The only G3-4 hematologic toxicity was neutropenia (G3, 25 %; G4, 9 %). 
      Early assessed DCE-MRI response parameters failed to predict pCR. CONCLUSIONS: 
      The neoadjuvant anthracycline-free combination of weekly paclitaxel and 
      carboplatin plus bevacizumab is active and safe in triple-negative breast cancer, 
      and the rate of pCR is comparable to that observed with more intensive 
      carboplatin- and bevacizumab-containing regimens. Further investigation is 
      warranted.
FAU - Guarneri, Valentina
AU  - Guarneri V
AD  - Department of Surgery, Oncology, and Gastroenterology, University of Padova, 
      Padua, Italy, valentina.guarneri@unipd.it.
FAU - Dieci, Maria Vittoria
AU  - Dieci MV
FAU - Bisagni, Giancarlo
AU  - Bisagni G
FAU - Boni, Corrado
AU  - Boni C
FAU - Cagossi, Katia
AU  - Cagossi K
FAU - Puglisi, Fabio
AU  - Puglisi F
FAU - Pecchi, Annarita
AU  - Pecchi A
FAU - Piacentini, Federico
AU  - Piacentini F
FAU - Conte, PierFranco
AU  - Conte P
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150109
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Contrast Media)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab/administration & dosage
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Ductal, Breast/*drug therapy/pathology
MH  - Contrast Media/*administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage
MH  - Preoperative Care
MH  - Prognosis
MH  - Triple Negative Breast Neoplasms/*drug therapy/pathology
EDAT- 2015/01/13 06:00
MHDA- 2016/05/14 06:00
CRDT- 2015/01/10 06:00
PHST- 2014/10/31 00:00 [received]
PHST- 2015/01/10 06:00 [entrez]
PHST- 2015/01/13 06:00 [pubmed]
PHST- 2016/05/14 06:00 [medline]
AID - 10.1245/s10434-015-4371-0 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2015 Sep;22(9):2881-7. doi: 10.1245/s10434-015-4371-0. Epub 2015 
      Jan 9.